Physician profile
Mark A Sutton
NPI 1699769935
$27,520.90
in general payments reported to CMS, 2019-2025
65 companies · $8,531 in 2025
The $8,531 reported for 2025 was more than what 93% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,459 · 2020: $1,041 · 2021: $797 · 2022: $2,986 · 2023: $6,023 · 2024: $5,683 · 2025: $8,531.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,011 · Long Term Medical Supply Or Device Loan: $5,143 · Consulting Fee: $4,000 · Education: $1,699 · Travel and Lodging: $1,366 · Entertainment: $18.94.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,010.77 |
| Long Term Medical Supply Or Device Loan | $5,142.85 |
| Consulting Fee | $4,000.00 |
| Education | $1,698.99 |
| Travel and Lodging | $1,365.66 |
| Entertainment | $18.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hmu Consumables, LLC | $5,142.85 | 2025 | Dornier Medtech |
| Edap Technomed INC | $4,237.89 | 2022-2024 | |
| Intuitive Surgical, INC. | $3,379.81 | 2022-2023 | Da Vinci Sp, Da Vinci Surgical System |
| Boston Scientific Corporation | $2,133.25 | 2019-2025 | Spaceoar Vue System - 10ml, Ams 700, Rezum Generator |
| Astellas Pharma US INC | $1,406.41 | 2019-2025 | Xtandi, Myrbetriq, Padcev |
| Biotissue Holdings INC. | $1,270.20 | 2022-2025 | |
| Sumitomo Pharma America, INC. | $779.00 | 2023-2025 | Gemtesa, Orgovyx |
| Janssen Biotech, INC. | $702.07 | 2019-2025 | Erleada |
| Pfizer INC. | $648.05 | 2019-2025 | |
| Abbvie INC. | $631.57 | 2019-2025 | Lupron Depot, Botox |
| Procept Biorobotics Corporation | $568.03 | 2019-2025 | Aquabeam System, Aquabeam Robotic System |
| Myriad Genetic Laboratories, INC. | $565.71 | 2020-2025 | Prolaris |
| Antares Pharma, INC. | $508.44 | 2020-2025 | Xyosted |
| Medtronic, INC. | $428.08 | 2022-2025 | Altaviva, Interstim |
| Urogen Pharma, INC. | $422.15 | 2021-2024 | Jelmyto |
Show all 65 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$14,814.84 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Sutton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.